This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More
by Zacks Equity Research
The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).
Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data
by Zacks Equity Research
Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of -31.25% and -39.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down
by Zacks Equity Research
The FDA issues a Complete Response Letter to ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock falls.
Do Options Traders Know Something About Celldex (CLDX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of -5.88% and 130.35%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Celldex Therapeutics (CLDX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celldex Initiates Early-Stage Antibody Study for Skin Disorder
by Zacks Equity Research
Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.
Is the Options Market Predicting a Spike in Celldex Therapeutics (CLDX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
5 Biotech Stocks Up More Than 100% This Year So Far
by Zacks Equity Research
Here we discuss five biotech companies recording impressive growth so far in 2020.
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for July 9th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 9th
Celldex Therapeutics, Inc. (CLDX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Celldex Therapeutics, Inc. (CLDX).
Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.
Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CLDX) Outperforming Other Medical Stocks This Year?
Is Celldex Therapeutics, Inc. (CLDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CLDX) Outperforming Other Medical Stocks This Year?
Celldex (CLDX) Soars: Stock Adds 10% in Session
by Zacks Equity Research
Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Seattle Genetics Gets Early FDA Nod for Breast Cancer Drug
by Zacks Equity Research
The FDA grants accelerated nod to Seattle Genetics' (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with advanced unresectable metastatic HER2-positive breast cancer.
Alnylam's Vutrisiran Gets Fast Track Tag for hATTR Amyloidosis
by Zacks Equity Research
The FDA confers a Fast Track status on Alnylam's (ALNY) RNAi therapeutic vutrisiran for treating adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Moleculin (MBRX) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Moleculin (MBRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
by Zacks Equity Research
The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).
Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
by Zacks Equity Research
Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
by Zacks Equity Research
Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
UroGen (URGN) Looks Good: Stock Adds 8.1% in Session
by Zacks Equity Research
UroGen (URGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.